JP3167402B2 - Iron absorption promotion composition - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

FIELD OF THE INVENTION The present invention relates to a peptide E for promoting iron absorption.
The present invention relates to an iron absorption-promoting composition containing SP-2 and DAN-100 as active ingredients, and a highly absorbable iron agent obtained by mixing or chelate-bonding these with citric acid and an iron compound.

[0002] The iron absorption-promoting composition and iron agent of the present invention can remarkably improve iron absorption, and are therefore suitable as health foods and drugs for ameliorating anemia.

[0003]

Prior to the present invention, the present inventors developed a novel peptide ESP-2 by treating fish meat with proteolytic enzymes and treating the resulting peptide stock solution with activated carbon (Japanese Patent Laid-Open No. 2-273144). ) And further subjecting it to ion-exchange treatment to obtain a novel peptide, Dan-100.
Was successfully developed (Japanese Patent Publication No. 3-54958).

[0004]

SUMMARY OF THE INVENTION In the present invention, the iron absorption promoting effect of a peptide obtained by treating fish meat with proteolytic enzymes has been confirmed. We will develop foods for specified health use.

[0005]

In order to solve the above-mentioned problems, as a result of investigations from various fields, it was decided to use natural products from the viewpoint of safety. Attention was paid to the peptide, DAN-100. And
As a result of thoroughly examining the physiological activity of DAN-100 and related substances, in addition to peptide DAN-100,
A new and useful finding was obtained that the peptide ESP-2 obtained by treating a raw material of fish meat proteolytic enzyme, which is the raw material thereof, with activated carbon has an excellent iron solubilizing action and iron absorption promoting action. The present invention has been made based on such useful new findings.

The peptide used in the present invention has been developed by the present inventors as described above,
For example, JP-A-2-273144, JP-B-3-5495
As described in No. 8, a peptide is produced by treating fish and shellfish with a proteolytic enzyme, followed by treatment with activated carbon to obtain peptide ESP-2, which is then subjected to alcohol fractionation and ion exchange resin. By processing
And if necessary, this process is repeated and separated,
Purification is performed to obtain peptide DAN-100.

[0007] The present peptide is produced using fish and shellfish as a raw material. First, the peptide is treated with a meat extractor, deboner or the like to separate fish meat. The raw materials are preferably as fresh as possible. The separated fish meat may be divided into about 10 kg of surimi and used as it is for the next process.
-20 to -50 ° C., for example, -30 ° C., is blown rapidly by blowing about cold air, and stored at -20 to -25 ° C.,
This may be appropriately used as needed.

[0008] As seafood, sardines, horse mackerels, tuna,
Skipjack, saury, mackerel and other lean fish; flounder, Thailand, kiss,
White fish such as Konoshiro, cod, herring, yellowtail; cartilage fish such as sharks and rays; freshwater fish such as smelt, carp, char, yamame; deep-sea fish such as eye sharks and anglers, as well as shrimp, crab, octopus, and mysid it can.

In the present invention, after the meat has been minced, the fish and shellfish are crushed by a crusher or the like, and no water is added.
0-fold amount of water, suitable temperature for enzyme (depending on enzyme used, 2
About 0 to 60 ° C), and the pH is adjusted to an appropriate value (pH 2 to 2).
11), add protease and add 1-30
Time processing. If desired, the ground fish and shellfish may be added to water and then kept in a stirred tank at about 40 to 60 ° C. for 1 to 5 hours to allow self-digestion, followed by addition of an enzyme to decompose.

As the proteolytic enzyme, any enzyme can be used alone or in combination as long as it is an enzyme capable of decomposing proteins. Its origin can be determined from microorganisms in addition to animals and plants, and in addition to pepsin, renin, trypsin, chymotrypsin, papain, bromelain, bacterial proteases, filamentous proteases, actinomycetes proteases and the like can be widely used. As these enzymes, those commercially available are generally used, but unpurified enzymes, culture solutions containing the enzymes, solid or liquid enzyme contents such as koji may also be used as necessary according to the purpose. Can be.

The amount of the proteolytic enzyme varies depending on the degree of purification of the enzyme and also varies depending on the treatment time, but it is sufficient to use 0.05 to 5%, preferably about 0.1% of the treatment solution. is there. In the case of using a 0.1% protease solution, when treating red meat such as sardine as fish meat, pH 4.1, about 17 hours at 45 ° C., or pH 5.
9. The enzyme treatment is completed in about 4 hours at 48 ° C.

After neutralization, the temperature is raised to a temperature of 80 ° C. or higher.
Hold for ~ 30 min to inactivate enzyme. After the heat inactivation treatment, the mixture is filtered through a vibro screen or the like, and if necessary, subjected to a Jector treatment.

After concentrating this by a conventional method (to about 30 Bx), it is centrifuged again to obtain a peptide stock solution.

Next, the peptide stock solution is decolorized by adding activated carbon and diatomaceous earth, filtered, and used as it is as a functional peptide stock solution. The functional peptide stock solution obtained here can be freeze-dried or spray-dried without or with the addition of dextrin to be powdered.

[0015] The functional peptide thus obtained is a novel peptide which has not been published in any literature, and has been identified by the present inventors as ESP.
-2.

The physicochemical properties of the peptide ESP-2 are as follows:
The results are shown in Tables 1 and 2 below.

[0017]

[Table 1]

[0018]

[Table 2]

The functional peptide ESP prepared as described above
-2 can be used as an active ingredient in the present invention as described below, but a peptide obtained by further purifying it has excellent functionality and can be used as an active ingredient in the present invention. The purification is performed as follows. First, alcohol is added to ESP-2 and left. As the alcohol, methanol, ethanol, propanol, isopropanol, butanol and the like are preferable,
You can use other alcohols. The alcohol is used in a cold state (0 to 10 ° C.), and is used in an amount equal to or more than 30 times as much as the peptide stock solution. After the addition of the cold alcohol, the mixture may be left in a cold room for 30 minutes to 3 hours or more to generate a precipitate, and may be further purified.

After adding water to the alcohol precipitate obtained above to form a solution, this solution is treated with an ion exchange resin. As the resin, a cation exchange resin, particularly a strongly acidic cation-crosslinked resin is used. For example, the above solution is injected into a column filled with these resins, washed with water, and then eluted with an aqueous alkaline solution such as dilute ammonium water to obtain an eluate.

The obtained eluate is subjected to the above treatment if necessary, after removing ammonia by a method such as concentration under reduced pressure, concentrated, and powdered by a method such as freeze-drying according to a conventional method. To obtain a basic peptide.
As described above, the eluate may be concentrated or diluted and used for various purposes.

The peptide thus obtained has been developed by the present inventors and is extremely useful, and was named DAN-100.

The physicochemical properties of peptide Dan-100 are shown in Tables 3 and 4 below.

[0024]

[Table 3]

[0025]

[Table 4]

As will be apparent from the following description, the peptides according to the present invention not only have an excellent iron solubilizing ability with respect to various iron salts, but also have an excellent iron absorption promoting action in vivo. It can be used for supplementing iron to humans, strengthening iron, preventing, treating and ameliorating iron deficiency anemia, and as an iron absorption promoting composition, for example, iron absorption promoter, food and drink, nutritional enhancement Used as food, functional food (food for specified health use), or animal and plant fertilizer feed additive, as a medicine, infusion,
It can be widely used as health food, clinical nutrition food, etc.

As will be apparent from the following description, the above-mentioned action is further amplified in the presence of citric acid and / or citrate, so that the peptide of the present invention, the iron compound and citric acid (salt) If the combination is used, the effect will be further enhanced. Therefore, an iron preparation containing a peptide and an iron compound, and an iron preparation further containing citric acid (salt) are used to prevent, treat, and improve various diseases caused by iron deficiency including iron deficiency anemia. It can be formulated in the form of pharmaceuticals, foods and drinks, feed additives and the like. The iron compound is not particularly limited, and iron chloride, ferrous sulfate, ferrous citrate, iron ammonium citrate, sodium iron citrate succinate, iron lactate, iron pyrophosphate, and other inorganic or organic irons The compound can be used appropriately, and the compounding amount may be the same as that of the commercially available iron agent. In the present invention, since the effect of promoting absorption of iron is high, even if a small amount of iron is blended, it can be effectively used. In addition, as the citric acid (salt), in addition to free citric acid, a sodium salt, a potassium salt, a calcium salt, a magnesium salt and other salts can be freely used as appropriate, and there is no particular limitation. And in this case, if a compound such as sodium ferrous citrate is used, citric acid and iron will be simultaneously compounded.

The detailed mechanism of the remarkable effect of the present invention must be studied in future studies.
ESP-2 and DAN-100 were eluted with an acetate buffer containing ferrous citrate using HPLC, and the iron concentration of the fractionated fraction was measured. A change in iron concentration was confirmed, suggesting that the iron absorption promoting effect of the sardine muscle-derived peptide was due to a chelate phenomenon with iron via citric acid. Therefore, the iron agent according to the present invention includes not only a mixture of the three components of peptide, citric acid and / or a salt thereof, and an iron compound, but also those obtained by chelating these three components.

The sardine-derived peptide (ES) according to the present invention
When P-2 and DAN-100) are used as an iron absorption promoting composition, particularly in a food or drink type, the peptide (liquid, paste or powder) may be added as it is, or may be added to other foods or food ingredients. It can be used in accordance with a conventional method as appropriate. When used as a pharmaceutical type such as an iron absorption promoter or an iron agent, it can be administered orally or parenterally. In the case of oral administration, for example, tablets, granules, powders, capsules, and powders can be prepared in the usual manner. In the case of parenteral administration, for example, injection preparations, drops, suppositories It can be used as an agent or the like.

The peptides according to the invention have no or very low toxicity because of their natural origin and are very safe (LD ₅₀ > 3000 mg / kg subcutaneous,> 5000
mg / kg orally: all rats).

Hereinafter, Production Examples and Examples of the present invention will be described.

[Preparation Example 1] Fresh sardines were treated with a body and minced. The minced fish meat was divided into 10 kg surimi. After crushing this with a crusher, add an equal amount of water,
The mixture was heated to 45 to 48 ° C., transferred to a stirring tank, kept at the same temperature for 2 to 3 hours, and allowed to self-digest and dissolve. Then p
H was adjusted to 4.1. To this, a 0.1% solution of denazyme (commercially available protease preparation) was added, and the mixture was heated at 45 ° C for 1 hour.
Enzymatic degradation was performed by holding for 7 hours. Neutralize, then 15
Boiled for minutes to inactivate the enzyme.

This was filtered through a vibro screen (150 mesh), and the filtrate was subjected to a Jector treatment at 5,000 rpm, followed by a Sharpless centrifuge (15000).
rpm), and concentrated by heating at room temperature until it became 20 Bx, and again subjected to a sharpless centrifugation (15,000 rpm) to obtain a peptide stock solution (DAN-No. 2).

[Preparation Example 2] 1840 ml of the peptide solution (pH 6.22) obtained above was taken, and activated carbon 1 was added thereto.
After stirring for 60 minutes, the mixture was filtered and the filtrate (pH
6.12) 1500 ml of (ESP-2) were obtained. Next, 100 ml of the filtrate was taken, and 20 ml of cold methanol was added thereto.
After adding 00 ml, the mixture was allowed to stand in a cold room for 60 minutes to cause precipitation. The resulting precipitate was added to water to obtain a solution (E).

[Production Example 3] 100 ml of the above solution (E) containing ESP-2 was taken, and this was added to Dowex 50W.
It was injected into a column (diameter 5 × 15 cm) packed with [H +]. Then, the resin is washed with 2000 ml of water,
It was eluted with N-NH ₄ OH250ml, After concentrating the resultant eluate was subjected to chromatographic treatment with Sephadex G-25 column. The obtained peptide fraction was subjected to Dowex column chromatography treatment, washing with deionized water, elution with ammonia water and concentration treatment in the same manner as described above, followed by lyophilization to give peptide DAN-100.
Was obtained as a white powder.

The thus prepared peptide ESP-
2 and DAN-100, Asahipak G
Using an S-320 column (diameter 4.0 mm x 45 cm),
High performance liquid chromatography (HPLC) was performed under the following conditions to obtain the pattern in FIG. Eluent: 45% acetonitrile in 0.1% trifluoroacetic acid, flow rate: 0.5 ml /
min, detection: UV 220 nm, marker: B = bacitracin (molecular weight 1,450), G = glycyl-tyrosine (molecular weight 238). As a result, 500 to 1 for ESP-2
Around 000, and also 500 for DAN-100
A molecular weight cutoff range of about ２，2,000 was shown.

[Example 1] Peptide ESP according to the present invention
-2, DAN-100 was subjected to an iron solubilization test (distilled water base and phosphate buffer base) at pH 7.0 for various iron samples. In addition, a casein peptide was used as a comparative control sample.

The iron assay was performed as follows. First, each peptide (protein content 0.1-0.5%)
In the case of a distilled water base (indicated by A in the drawing), add 2.5 ml of distilled water, and in the case of a phosphate buffer base (indicated by B in the drawing), add 2 mM of a 600 mM phosphate buffer (pH 6.8). .5 ml and add with HCl
After adjusting H to 2.5, a standard solution of iron (Fe: 100
0 ppm), and add 0.1 ml each, and adjust the pH with HCl.
Was adjusted to 2.0, and then kept at room temperature for 30 minutes.
The pH was adjusted to 7.0 with. This was diluted to 10 ml, kept at 37 ° C for 30 minutes, and filtered (Toyo, N
o. 2). For the filtrate, a polar Zeeman atomic absorption spectrophotometer (Hitachi, HITACHI Z-61)
00), the iron content was determined. Then, the iron content of each peptide to which iron was not added was determined in the same manner as described above, and the subtraction value was defined as the iron solubilization amount.

According to the method described above, five types of iron samples, iron chloride (FeCl ₂ ), ferrous sulfate (FeSO ₄ ),
Sodium ferrous citrate (FeNaH (C ₆ H
_The iron solubilization rate was measured for ₈ O ₇ ) ₂ ), citric acid-added iron chloride, and citric acid-added ferrous sulfate.
To FIG. 6 were obtained. In each figure, A shows data on the basis of distilled water, and B shows data on the basis of 150 mM phosphate buffer. In each test,
The content of iron and citric acid was 100 μg / 10 ml.

As is clear from the above results, it was proved that the sardine muscle-derived peptide exhibited excellent iron solubilizing ability, and in particular, the iron solubilizing ability was significantly increased in the presence of citric acid. That is, as shown in FIG. 2, the casein peptide had a higher iron solubilization rate with respect to the iron chloride, but as apparent from FIG. 3, the casein peptide was based on the phosphate buffer using ferrous sulfate. , The iron solubilization rate decreased, and DAN-100 showed a higher iron solubilization rate.
As is clear from FIG. 4, when sodium ferrous citrate was used, ESP-2 and DAN-1 were used for both bases.
The iron solubilization rate was higher than that of casein peptide on a phosphate buffer basis. As is clear from FIGS. 5 and 6, compared with the case of using iron chloride (FIG. 2) and ferrous sulfate (FIG. 3) alone, the addition of citric acid resulted in
While the iron solubilization rate of SP-2 and DAN-100 was increased, the iron solubilization rate of the casein peptide was not improved.

Example 2 Sardine muscle-derived peptide (E
Regarding SP-2), the effect of promoting iron absorption was examined using iron deficiency anemia model rats, and the effect of improving iron deficiency anemia was confirmed.

That is, an anemia recovery test was performed using an iron deficiency anemia model rat according to the procedure shown in Table 5 below. In other words, male SD rats were bred for 4 weeks on an iron-deficient diet and used as an iron-deficient anemia model rat, and then a control group to which only ferrous sodium citrate was given, a sardine peptide ESP-2 was treated with ferrous citrate. The group given 1.25% and 5.00% each with sodium was 40
They were bred for days. Furthermore, normal rats fed from a normal diet from the beginning were used as normal rats. Hemoglobin amount every 10 days,
Hematocrit values were determined on the last day for serum iron and unsaturated iron binding capacity.

[0043]

[Table 5]

The composition of the iron deficient feed is shown in Table 6 below. The compositions of the mineral mixture and the vitamin mixture in the iron-deficient feed are shown in Tables 7 and 8 below. In this example, an iron-deficient anemia model rat was prepared using this iron-deficient diet, and sodium ferrous citrate was added to the rat.
A sample to which mg / 100 g (10 ppm as Fe) was added was used as an experimental sample (control group).

[0045]

[Table 6]

[0046]

[Table 7]

[0047]

[Table 8]

The measured values of the mineral components in the experimental samples are as shown in Table 9 below, and the measured values of the mineral components of ESP-2 are as shown in Table 10 below. Therefore, in this example, ESP-2 was used as an experimental sample.
Even when 25% and 5.00% are added, the values of the mineral components are almost the same.

[0049]

[Table 9]

[0050]

[Table 10]

The results of changes in body weight and feed intake in the recovery test of iron deficient anemia rats are as shown in FIGS. 7 and 8. As is evident from these results, in the sardine peptide ESP-2 added group, a slight nutritional effect of the peptide was observed, but no statistically significant difference was observed. As for the feed intake, the sardine peptide ESP-2 added group had a somewhat higher intake due to free intake, but there was no statistically significant difference.

The results of changes in blood hemoglobin amount and blood hematocrit during the anemia recovery test process are shown in FIG.
10 and FIG. As is clear from these results, the recovery of the hemoglobin amount by the addition of iron from the anemia state was less than 20% in the sardine peptide ESP-2 added group.
A significant effect was shown on and after the day.
On day 0, it recovered to a level of 90% of normal rats. The speed of recovery was sardine peptide ESP-2.
Dose response of addition was observed. In addition, the change in blood hematocrit during the process of anemia recovery test showed a good recovery promoting effect as in the case of the hemoglobin amount.
After the day, a significant difference was observed in a dose-dependent manner. On the 40th day, the ESP-2 5.00% addition group recovered to a level almost equal to that of the normal rat.

Analysis of four parameters, serum iron (Fe), unsaturated iron binding capacity (UIBC), total iron binding capacity (TIBC) and saturation rate (BR) in heart blood serum 40 days after the anemia recovery test Then, the results shown in Table 11 below were obtained.

[0054]

[Table 11]

In the above, serum iron is nitroso PSAP
It was measured by the method. As is clear from the above results, the Dose resp was higher in the ESP-2 added group than in the control group.
once, and a significant difference was observed. Especially 5.00
The% -added group recovered to 90% or more of normal rats.

The unsaturated iron binding ability was measured by the method of Genban et al. As is clear from the above results, this also showed significant recovery in a dose-dependent manner as compared with the control group. The iron saturation in the blood calculated from this was 46% in the control group as compared with the normal rat, while 67% in the sardine peptide ESP-2 1.25% added group and 82 in the 5.00% added group. %, Which is twice the effect of the control group.

As is clear from the above results, ESP-2
By adding, the iron solubilization rate of various iron salts was increased. Regarding the iron deficiency anemia model rat, no significant difference was observed in the body weight and the amount of food consumed, and the hemoglobin amount and the hematrit value significantly recovered after the 20th day.
The binding rate calculated from the recovery of serum iron and the binding ability of unsaturated iron also showed a significant difference depending on the dose of ESP-2, confirming that it was effective in improving iron deficiency anemia. In other words, it has been demonstrated that the sardine muscle-derived peptide has a significant effect on iron deficiency anemia, especially when used in combination with citric acid. This effect is ES
Not only P-2 but also a peptide containing the active ingredient, for example, DAN-100, is naturally exerted.

[Example 3] A sardine muscle-derived peptide according to the present invention, ESP-2 and DAN-100,
sahipak GS-320 (diameter 4.0mm × 45c)
m) and high performance liquid chromatography (H
PLC) and eluted with an acetate buffer containing ferrous citrate. The iron concentration was measured for the fractions (the iron concentration in the buffer was almost the same as when measuring the iron solubilizing ability).
And the result of FIG. 12 was obtained.

HPLC conditions: Eluent: 0.01M acetate buffer (pH 4.0) / ferrous sodium citrate (FeNaH (C ₆ H ₈ O ₇ ) ₂ ) (Fe: 10.4 p
pm), flow rate: 0.5 ml / min, fractionation: 1.0 m
l.

As is evident from the above results, a change in iron concentration was observed in all the peptides in the same pattern as the elution pattern of the peptide. Therefore, in a state in which the peptide and ferrous citrate are dissolved and solubilized, the peptide and ferrous citrate are not dissolved individually, but form a complex and are dissolved. It can be seen that chelation is occurring. This strongly suggested that the iron absorption promoting effect of the sardine muscle-derived peptide was due to the chelating effect of iron with citric acid.

Example 4 To 20 g of vitamin C, 10 g of ferrous sulfate, 40 g of granulated sugar, and 30 g of an equal mixture of corn starch and lactose, 50 g of the peptide Dan-100 obtained in Example 3 was added and mixed well. . The mixture was divided into 100 equal parts and packed into bags, and 100 bags of 1.5 g of nutritional health food sticks having an iron absorption promoting property were produced per bag.

Example 5 The peptide ESP-2 obtained in Example 2 was used in place of the peptide DAN-100, and 20 g of vitamin C was replaced with 20 g of an equal mixture of vitamin C and citric acid. After the same treatment as in Example 4 was repeated and dried sufficiently, an iron absorption-promoting nutritional health food was produced.

Example 6 An iron agent was produced according to the following formulation. (1) 250 g of the peptide ESP obtained in Example 2,
(2) 10 g of ferrous sulfate, (3) 10 g of citric acid,
(4) lactose 70 g, (5) corn starch 2
9 g, (6) 1 g of magnesium stearate.

First, (1), (2), (3), (4) and (5) (17 g) were mixed, and (5) (7 g)
Granulated with the paste prepared from (5) (but 5 g) and (6) are added to the obtained granules and mixed well,
This mixture was compressed using a compression tablet machine to produce 100 tablets containing 10 mg of iron per tablet.

The dose varies depending on the patient's condition and age, but is 0.1 to 1000 mg / kg / day, once a day.
Administer ~ 4 times. Since the peptide used in the present invention is originally derived from food, there is almost no problem in safety as described above, and therefore, it is safe to administer more than the above dose. In addition, health maintenance, promotion, health,
When this is used as a nutritional supplement or the like, a smaller dose than the above dose may be taken for a long period of time. As described above, the iron preparation according to the present invention can be administered by a method other than oral administration. In the case of intravenous administration and intramuscular administration, the dosage is 0.01 to 1000 mg / kg / day. Can be administered in the same manner as described above.

Example 7 The following composition was prepared. (1)
10 g of ESP-2 obtained in Example 2, (2) iron chloride 1
g, (3) 1 g of sodium citrate, (4) 8 g of sodium chloride, (5) 4 g of chlorobutanol, (6)
1 g of sodium bicarbonate.

All the components were dissolved in 1000 ml of distilled water, and this was dispensed into two 500 ml drip bottles to obtain an iron-containing nutrient infusion.

[0068]

According to the present invention, by using the sardine muscle-derived peptides ESP-2 and DAN-100,
Iron absorption is enhanced and it is further amplified by the incorporation of citric acid. Therefore, since the iron absorption enhancer and iron agent according to the present invention have significantly improved iron absorption, an iron absorption composition for improving anemia, such as a health food,
It is suitable as a drug.

[Brief description of the drawings]

FIG. 1 shows the HPLC pattern of ESP-2 and DAN-100.

FIG. 2 shows the iron solubilization ratio of each peptide when iron chloride (FeCl ₃ ) was used.

FIG. 3 shows the iron solubilization rate of each peptide when ferrous sulfate (FeSO ₄ ) was used.

FIG. 4. Ferrous sodium citrate (FeNaH (C ₆
H ₈ O _{7) 2)} shows the iron solubilization rate of each peptide when using.

FIG. 5 shows the iron solubilization rate of each peptide when citric acid was added using iron chloride.

FIG. 6 shows the iron solubilization ratio of each peptide when ferrous sulfate was used and citric acid was added.

FIG. 7 shows changes in rat body weight in a recovery test of iron-deficient anemia rats.

FIG. 8 shows the amount of feed fed to iron-deficient anemic rats.

FIG. 9 shows changes in the amount of hemoglobin in the process of recovery from anemia.

FIG. 10 shows the change in hematocrit during the recovery process from anemia.

FIG. 11. H of ESP-2 with eluent containing ferrous sulfate
3 shows a PLC pattern.

FIG. 12. DAN-100 with ferrous sulfate containing eluent
3 shows the HPLC pattern of the sample.

FIG. 13 shows a UV spectrum of ESP-2.

FIG. 14 shows an IR spectrum of ESP-2.

[Explanation of symbols]

 ：: ESP-2 □: DAN-100 △: Casein peptide A: distilled water B: buffer

Continuation of the front page (51) Int.Cl. ⁷ identification code FI A61P 3/02 A61P 3/02 7/06 7/06 C12P 21/06 C12P 21/06 (58) Fields surveyed (Int.Cl. ⁷ , DB name) A61K 38/00 BIOSIS (DIALOG) CA (STN) MEDLINE (STN) EMBASE (STN)

Claims (6)

(57) [Claims] 1. Peptide ESP-2 or peptide DAN
An iron absorption promoting composition containing -100 as an active ingredient. 2. The iron absorption promoting composition according to claim 1, wherein the composition is an iron absorption promoting agent or an iron absorption promoting food or drink. 3. An iron preparation comprising the peptide ESP-2, citric acid and an iron compound. 4. An iron preparation comprising the peptide Dan-100, citric acid and an iron compound. 5. The iron compound is selected from the group consisting of iron chloride, ferrous sulfate, ferrous citrate, iron ammonium citrate, iron sodium succinate, iron lactate and iron pyrophosphate. The iron agent according to claim 3 or 4. 6. The method according to claim 3, wherein the iron agent is obtained by simply mixing the peptide, citric acid and an iron compound, or is obtained by chelating the compound. Iron agent.